Back to news

How AI and Anticancer Peptides Could Reshape the Future of Cancer Treatment

Globe Newswire•18/11/2026•08:30 ET
0

Key Highlights

  • ➤DataMEDS-Helomics partnership accesses 70,000+ primary tumor biobank for cancer target discovery
  • ➤DataMEDS will issue 630,000 shares to DiaGen, equal to 9.9% outstanding
  • ➤NeoGenomics expanded Indica Labs partnership, adopting HALO AP cloud-based digital pathology platform
  • ➤Anthropic’s life sciences team has research partnerships with six medicine developers
  • ➤Recursion’s REC-4881 showed persistent GI polyp burden reductions in new TUPELO data

Expert Statements

Mohit Pandey, Chief AI Officer of DiaGen.ai

“Being able to access this robust primary tumor biobank and Helomics’ proprietary capabilities to identify new therapeutic targets and leverage our proprietary BLACKCOMB artificial intelligence chemical drug discovery platform to design the best candidates for human clinical development is a transformative opportunity for DiaGen.”

Mohit Pandey, Chief AI Officer of DiaGen.ai

“Building upon the foundational methodologies in my recent peer-reviewed research in Nature Communications, we know that the only way for artificial intelligence companies in the biotechnology space to truly differentiate themselves is to train their models on unique, high-dimensional biological data in areas of high unmet medical need. With this agreement, DiaGen is gaining access to an untapped resource of real-world tumor data upon which to build a novel intellectual property portfolio together with Helomics.”

Gerald Commissiong, Interim Co-CEO of DataMEDS

“We are excited to have identified our first partner that begins the process of monetizing the unique resources in our lab and will help us unlock the tremendous value resident in one of the world’s largest curated biobanks while also allowing us to participate in the long-term value creation of biotechnology drug discovery”

Gerald Commissiong, Interim Co-CEO of DataMEDS

“Helomics is also now open to establish new practicing oncologist relationships for its commercially available ChemoFx® Assay, as well as re-activate historical relationships, which will help us continue to grow the size and diversity of the Helomics Biobank. Partnering with DiaGen lets us contribute to the creation of groundbreaking new therapies that can improve the standard of care for patients with cancer while allowing us to participate in the value of the new intellectual property created leveraging our unique resources.”

Najat Khan, President and Chief Executive Officer of Recursion

“To pioneer a new blueprint for making medicines with AI, we believe you have to tie together three core capabilities in one engine: uncover novel biology, design differentiated molecules against challenging targets, and generate clinical evidence that matters for patients.”

Najat Khan, President and Chief Executive Officer of Recursion

“The new TUPELO data are important clinical evidence, with REC-4881 showing deep polyp burden reductions across the upper and lower GI tract, including larger, higher-risk polyps, and reductions that persist after treatment stops. REC-1245 is an encouraging early example of that engine coming together within a single program, from biological insight surfaced by our platform to molecule design and now early clinical signals in heavily pretreated patients.”

NEW YORK, Nov. 18, 2026 (GLOBE NEWSWIRE) -- Artificial intelligence is giving cancer researchers a powerful new way to find potential drug targets and develop treatments that may have been difficult or time-consuming to discover using traditional methods. By sorting through massive amounts of genetic, molecular, and biological data, AI platforms can help pinpoint weaknesses in cancer cells, identify promising drug candidates, and predict how different compounds may behave. What once required years of research and extensive laboratory screening can increasingly be narrowed down with the help of advanced algorithms. The financial opportunity is growing just as quickly. The global AI drug discovery market was estimated at approximately $2.3 billion in 2025 and is projected to reach $13.8 billion by 2033, according to Grand View Research. The broader AI in oncology market represents another major opportunity, with estimates pointing to growth from approximately $6 billion in 2025 to $38.9 billion by 2033. Precedence Research reported the global cancer therapeutics market size was estimated at USD $212.58 billion in 2025 and is predicted to increase from approximately USD $232.14 billion in 2026, to approximately USD $501.07 billion by 2035, expanding at a CAGR of 8.95% between 2026 and 2035. Today’s Leading Companies At the Forefront of AI and Healthcare Momentum Include: DataMEDS AI Inc. (NASDAQ: MEDS), NeoGenomics, Inc. (NASDAQ: NEO), Anthropic, PBC's (NASDAQ: ANT), Recursion (NASDAQ: RXRX), Orchestra BioMed Holdings, Inc. (NASDAQ: OBIO).

Get started

Create a free account to read the full story.

Sign Up

Already have an account? Log in